These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21987609)

  • 1. Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
    Ganslmayer M; Zimmermann A; Zopf S; Herold C
    World J Gastroenterol; 2011 Aug; 17(31):3623-9. PubMed ID: 21987609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
    Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
    Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma.
    Ganslmayer M; Ocker M; Kraemer G; Zopf S; Hahn EG; Schuppan D; Herold C
    J Hepatol; 2004 Jun; 40(6):952-6. PubMed ID: 15158335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
    Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG
    Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.
    Banerjee S; Zvelebil M; Furet P; Mueller-Vieira U; Evans DB; Dowsett M; Martin LA
    Cancer Res; 2009 Jun; 69(11):4716-23. PubMed ID: 19435899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
    Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
    Murakami M; Kobayashi S; Marubashi S; Tomimaru Y; Noda T; Wada H; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Ann Surg Oncol; 2011 Feb; 18(2):589-96. PubMed ID: 20811948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
    Schoenberger J; Grimm D; Kossmehl P; Infanger M; Kurth E; Eilles C
    Endocrinology; 2004 Mar; 145(3):1031-8. PubMed ID: 14607854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.